Raymond James Financial’s Exelixis EXEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$51.2M Sell
941,571
-104,024
-10% -$5.06M 0.01% 927
2026
Q1
$44.8M Buy
1,045,595
+181,367
+21% +$7.8M 0.01% 925
2025
Q4
$37.9M Sell
864,228
-78,153
-8% -$3.23M 0.01% 1000
2025
Q3
$38.9M Buy
942,381
+55,727
+6% +$2.24M 0.01% 963
2025
Q2
$39.1M Buy
886,654
+286,628
+48% +$11.5M 0.01% 909
2025
Q1
$22.2M Buy
600,026
+88,147
+17% +$3.14M 0.01% 1228
2024
Q4
$17M Buy
+511,879
New +$16.6M 0.01% 1440

Other funds holding EXEL

Raymond James Financial's EXEL Position: Q2 2026 in Review

Raymond James Financial reduced its Exelixis (EXEL) stake by 9.9% in Q2 2026, selling an estimated $5.06M and leaving 941,571 shares worth $51.2M. The position accounts for 0.01% of the portfolio, ranked #927.

Raymond James Financial first reported a position in EXEL in Q4 2024 and has held it in 7 quarters since. 760 funds tracked by Wall St. Rank hold EXEL as of Q2 2026.

  • Raymond James Financial held 941,571 shares of Exelixis worth $51.2M as of Q2 2026.
  • Raymond James Financial sold 104,024 Exelixis shares in Q2 2026, an estimated $5.06M.
  • Exelixis made up 0.01% of Raymond James Financial's portfolio in Q2 2026, its #927 holding.
  • Raymond James Financial first reported a position in Exelixis in Q4 2024 and has held it in 7 quarters since.
  • 760 funds tracked by Wall St. Rank held Exelixis as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.